Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Celcuity Inc.

Get SEC filing alerts via email and in your feed for Celcuity Inc.

CELC

Celcuity Inc.

About Celcuity Inc.

Celcuity Inc. is a biotechnology company specializing in targeted cancer therapies and diagnostic platforms. Its lead drug candidate, gedatolisib, inhibits key pathways involved in tumor growth, focusing on breast and prostate cancers. The company develops and commercializes therapies addressing unmet medical needs, leveraging proprietary IP and diagnostic tools to improve treatment efficacy and patient outcomes in solid tumors.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Celcuity Inc.

1
1
Celcuity Inc. Celcuity Reports $52.8 Million Net Loss in Q1 2026, Increases R&D and Operating Expenses

Via official filing (AI summary) | 20 days ago | 0 comments

2
1
Celcuity Inc. Celcuity Reports $177M Net Loss for Fiscal Year 2025 Amid Clinical Trials for Gedatolisib

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Celcuity Inc. Celcuity Reports $43.8 Million Net Loss in Q3 2025, Cash Reserves Increase to $74.3 Million

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Celcuity Inc. Celcuity Reports $45.3 Million Net Loss in Q2 2025, Increases Investment in Clinical Trials

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Celcuity Inc. Celcuity Reports $37M Net Loss in Q1 2025, Increases R&D Spending Amid Clinical Trials

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Celcuity Inc. Celcuity Reports $111.8 Million Net Loss and Advances Clinical Trials for Gedatolisib

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Celcuity Inc. Celcuity Inc. Reports Financial Developments, Increases Research and Development Expenses, and Raises $138.3 Million in Funding

Via official filing (AI summary) | over 1 year ago | 0 comments